Kodiak Sciences Inc. develops retinal medicines as a precommercial biotechnology company focused on diseases that can cause vision loss. News about KOD centers on the ABC Platform and ABCD Platform, the anti-VEGF biologic Zenkuda (tarcocimab tedromer), and bispecific programs including KSI-501 and KSI-101.
Recurring updates cover clinical data in diabetic retinopathy, wet age-related macular degeneration and macular edema secondary to inflammation, along with scientific conference presentations, financial results and capital formation. Company announcements also discuss pipeline expansion into multi-target retinal and ocular disease approaches, including programs directed at inflammation, geographic atrophy and glaucoma optic neuropathy.
Kodiak Sciences (NASDAQ: KOD) reported Q1 FY2026 results and clinical updates on May 7, 2026. Key clinical highlights: positive Phase 3 GLOW2 topline for Zenkuda in diabetic retinopathy (62.5% ≥2-step DRSS vs 3.3% sham; 85% reduction in sight‑threatening complications), DAYBREAK enrollment ~690 completed, and PEAK/PINNACLE advancing for KSI-101. Financials: $169.5M cash on hand and $58.2M net loss for the quarter; company expects cash to fund operations into 2027.
Kodiak Sciences (Nasdaq: KOD) will present clinical and preclinical advances May 2–7, 2026, at AUS and ARVO, including KSI-101 Week 24 MESI results and an Asian tertiary‑care cohort.
Key disclosed outcomes: 58% of Asian patients achieved ≥15‑letter BCVA gains; mean +17.8 letters at Week 24; CST reduced to <325 µm after one injection; >90% resolved IRF/SRF by Week 8 in APEX.
Kodiak Sciences (Nasdaq: KOD) reported Q4 and full-year 2025 results and program updates on March 31, 2026. Key highlights: positive Phase 3 GLOW2 topline for Zenkuda with 62.5% vs 3.3% ≥2-step DRSS improvement and 85% risk reduction for sight-threatening complications, intent to accelerate a multi-indication BLA, KSI-101 strong Phase 1b APEX data, DAYBREAK enrollment ~690 with topline in Sept 2026, cash $209.9M and $173.0M net proceeds from an 8.0M-share offering supporting operations into 2027.
Kodiak Sciences (Nasdaq: KOD) reported positive topline GLOW2 Phase 3 results for Zenkuda (tarcocimab tedromer) on March 26, 2026. Zenkuda met the primary endpoint with 62.5% achieving ≥2-step DRSS improvement versus 3.3% for sham (p<0.0001) and showed an 85% risk reduction in sight-threatening complications (2.4% vs 15.8%, p=0.0001). Safety was favorable with 0% intraocular inflammation and low cataract rates (2.3% vs 1.6%). Kodiak says Zenkuda has a multi-indication BLA-ready profile and intends to accelerate BLA submission plans.
Kodiak Sciences (Nasdaq: KOD) will present final Phase 1b APEX clinical results for KSI-101 in macular edema secondary to inflammation (MESI) at the virtual Angiogenesis meeting on February 7, 2026.
Dr. Sumit Sharma will present Week 24 end-of-study data at 5:15 PM ET; the presentation will be posted in the company's Events and Presentations section. The company says the final data show robust anatomic and visual improvements and continue to support the safety profile of KSI-101 while Phase 3 PEAK and PINNACLE studies remain actively enrolling.
Kodiak Sciences (Nasdaq: KOD) said senior management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026 at 1:30 p.m. PT.
A live webcast will be available on the company’s Events and Presentations page at http://ir.kodiak.com/ and will remain available for replay for a limited time after the event.
Kodiak Sciences (Nasdaq: KOD) closed an underwritten public offering of 8,000,000 common shares, including 1,043,478 shares sold under the underwriters' full option exercise, at $23.00 per share.
The gross proceeds to Kodiak Sciences were approximately $184 million before underwriting discounts, commissions and estimated offering expenses. The offering used a shelf registration declared effective June 2, 2023, and the final prospectus supplement is filed with the SEC.
Joint book-running managers were J.P. Morgan, Jefferies, Evercore ISI and UBS Investment Bank. Management said the transaction strengthens the company’s financial position as it advances Phase 3 topline readouts for KSI-101, KSI-501 and tarcocimab.
Kodiak Sciences (Nasdaq: KOD) priced an upsized underwritten public offering of 6,956,522 shares of common stock at $23.00 per share, producing expected gross proceeds of approximately $160 million before underwriting discounts, commissions and expenses.
The offering is expected to close on or about December 18, 2025, subject to customary closing conditions. Kodiak granted underwriters a 30-day option to buy up to an additional 1,043,478 shares at the public offering price less underwriting discounts and commissions. All shares are being sold by Kodiak Sciences.
J.P. Morgan, Jefferies, Evercore ISI and UBS Investment Bank are joint book-running managers. The shares are offered under a shelf registration on Form S-3 declared effective June 2, 2023, and prospectus materials have been filed with the SEC.
Kodiak Sciences (Nasdaq: KOD) announced a proposed underwritten public offering of 6,000,000 shares of common stock with a 30-day option for underwriters to purchase up to an additional 900,000 shares at the public offering price, less underwriting discounts and commissions. All offered shares will be sold by Kodiak Sciences and the offering is subject to market and other conditions. The shares are being offered pursuant to a shelf registration on Form S-3 declared effective by the SEC on June 2, 2023. J.P. Morgan, Jefferies, Evercore ISI and UBS are joint book-running managers.
Kodiak Sciences (Nasdaq: KOD) reported Q3 2025 results and business highlights on Nov 13, 2025. The company ended Q3 with $72.0 million cash and posted a Q3 net loss of $61.5 million ($1.16 per share). Clinical progress included week-20 APEX data for KSI-101 showing >50% of patients with ≥15-letter BCVA gains and ≥90% retina dryness at top doses, faster-than-expected PEAK/PINNACLE enrollment, and completed enrollment (~690 subjects) in Phase 3 DAYBREAK. Multiple Phase 3 topline dates are on track across 1Q–4Q 2026–2027 and a planned BLA filing is targeted after 2026 readouts.